Multiple Endocrine Neoplasia Type 1 (MEN1)

Multiple Endocrine Neoplasia Type 1 (MEN1), historically called Wermer syndrome after Paul Wermer who described familial clusters of pituitary, pancreatic, and parathyroid tumors in 1954, is a rare autosomal dominant hereditary cancer predisposition syndrome. It causes tumors to form in multiple endocrine glands simultaneously — most characteristically in the parathyroid glands, the pituitary gland, and the pancreatic-duodenal neuroendocrine cells. The condition arises from inactivating mutations in the MEN1 tumor suppressor gene on chromosome 11q13, which encodes the nuclear scaffold protein menin. With a prevalence of roughly 1 in 30,000 individuals, MEN1 accounts for a disproportionate share of morbidity from endocrine tumors because of its early onset, multiglandular involvement, high penetrance, and lifelong requirement for surveillance.

Table of Contents

  1. Overview
  2. Genetics and Pathogenesis
  3. The Three P's — Classic Triad
  4. Parathyroid Disease
  5. Pancreatic and GI Neuroendocrine Tumors
  6. Pituitary Adenomas
  7. Other Manifestations
  8. Diagnosis and Surveillance Protocol
  9. Treatment Principles
  10. Research Papers
  11. Connections

1. Overview

MEN1 is defined clinically by the simultaneous or sequential occurrence of tumors in at least two of the three classical endocrine sites: parathyroid glands, the anterior pituitary, and the endocrine pancreas or duodenum. A patient with one of these tumors plus a first-degree relative confirmed to carry a MEN1 mutation also meets the clinical definition. Familial MEN1 is diagnosed when two or more first-degree relatives have at least one of the classic MEN1-associated tumors.

The syndrome was first formally described in 1954 by internist Paul Wermer, who documented multiglandular adenomatous disease in a family across multiple generations. Earlier observations of combined parathyroid and pituitary or pancreatic tumors date to the 1930s, but Wermer recognized the hereditary pattern. The MEN1 gene itself was identified in 1997 by Chandrasekharappa and colleagues at the National Institutes of Health, a milestone that enabled genetic testing and presymptomatic identification of carriers.

Nearly all individuals who carry a germline MEN1 mutation will develop clinically significant disease by age 50, making penetrance effectively complete over a lifetime. The syndrome does not preferentially affect one sex, though specific tumor types may have different frequencies between men and women. Thymic carcinoids, for instance, occur almost exclusively in male MEN1 carriers who smoke.

Because the tumors in MEN1 are multiple, bilateral, multifocal, and prone to recurrence, management differs substantially from sporadic endocrine tumors. Lifelong annual surveillance is the cornerstone of care, and genetic cascade testing of at-risk family members beginning in childhood is a standard recommendation.

Back to Table of Contents

2. Genetics and Pathogenesis

The MEN1 gene is located on the long arm of chromosome 11 at band 11q13. It spans approximately 9 kilobases of genomic DNA and comprises 10 exons encoding a 610-amino-acid protein called menin. Menin is a nuclear scaffold protein with no homology to other known proteins; it functions primarily as a component of the MLL/SET1 histone methyltransferase complex, which deposits the activating histone mark H3K4 trimethylation (H3K4me3) at gene promoters. Through this chromatin-remodeling activity, menin regulates transcription of a broad set of genes governing cell proliferation, differentiation, and apoptosis. Loss of menin function removes a critical brake on cell division in endocrine tissues, eventually leading to benign and malignant tumors.

The MEN1 gene acts as a classical tumor suppressor, following Alfred Knudson's two-hit model. The germline mutation inherited from an affected parent constitutes the first hit: every cell in the body carries one non-functional copy of the gene from birth. The second hit — somatic loss of heterozygosity (LOH) at 11q13 in a specific endocrine cell — inactivates the remaining wild-type allele. Only that cell and its descendants form a tumor. Because somatic LOH is a random event, different glands undergo the second hit at different times, explaining the sequential, multifocal nature of MEN1 tumors.

More than 1,300 distinct germline mutations in MEN1 have been catalogued. Frameshift mutations and nonsense mutations together account for approximately 75% of cases; the remainder include splice-site mutations, missense mutations, and whole-gene deletions. Roughly 90% of mutations are predicted to produce a truncated or absent menin protein, consistent with a loss-of-function mechanism. There is no strong genotype-phenotype correlation — families with identical mutations can display widely varying tumor profiles and ages of onset. De novo mutations account for approximately 10% of MEN1 cases, meaning a negative family history does not exclude the diagnosis.

The prevalence of MEN1 is estimated at 1 in 30,000 in the general population, making it the most common hereditary multiple endocrine neoplasia syndrome after MEN2. Penetrance is nearly 100% by age 50 when biochemical and imaging surveillance is applied, though some carriers remain clinically silent until their sixth or seventh decade.

Back to Table of Contents

3. The Three P's — Classic Triad

Endocrinologists often teach MEN1 using the mnemonic of the Three P's: Parathyroid, Pituitary, and Pancreas (or more precisely, pancreatic-duodenal neuroendocrine tumors). These three sites are affected in 95%, 30–40%, and 30–75% of patients respectively over a lifetime of follow-up, depending on the surveillance intensity and patient age.

The parathyroid glands are nearly universally involved and are typically the first manifestation to appear, usually in the second or third decade of life. The pancreatic and duodenal neuroendocrine tumors (pNETs) tend to emerge in the third or fourth decade and carry the greatest risk of malignancy. Pituitary adenomas are often discovered on surveillance imaging; prolactinomas predominate and are frequently manageable with medication alone.

What distinguishes MEN1-associated tumors from their sporadic counterparts is the tendency toward multifocality and bilaterality. A patient with sporadic primary hyperparathyroidism typically has a single enlarged parathyroid gland; a MEN1 patient has all four glands hyperplastic. A sporadic insulinoma is virtually always solitary; MEN1 patients may have dozens of pNETs scattered through the pancreas and duodenal wall simultaneously. This fundamental difference drives the distinct surgical and surveillance strategies required in MEN1.

Back to Table of Contents

4. Parathyroid Disease

Primary hyperparathyroidism (PHPT) is present in 95–100% of MEN1 patients and is the most common first clinical manifestation of the syndrome. It typically presents between the ages of 15 and 30 — one to two decades earlier than sporadic PHPT, which peaks in postmenopausal women. Biochemically, MEN1-associated PHPT is indistinguishable from sporadic disease: elevated serum calcium combined with inappropriately elevated or high-normal parathyroid hormone (PTH).

The key pathological distinction is multiglandular parathyroid hyperplasia. In sporadic PHPT, a single adenoma accounts for roughly 85% of cases. In MEN1, all four parathyroid glands are typically enlarged and hyperfunctional, though the degree of enlargement varies among glands and over time. This multiglandular involvement has critical surgical implications: standard parathyroidectomy targeting a single gland, appropriate for sporadic disease, will reliably fail in MEN1 because the remaining glands will continue to overproduce PTH.

The consequences of untreated hypercalcemia in MEN1 include nephrolithiasis (kidney stones, present in 25–50% at diagnosis), nephrocalcinosis, osteoporosis with elevated fracture risk, and the classical neuromuscular symptoms of hypercalcemia — fatigue, cognitive dulling, depression, muscle weakness, constipation, and polyuria. Hypercalcemia also worsens ZES (Zollinger-Ellison syndrome) by stimulating gastric acid secretion, creating a clinical interaction between two of the Three P's.

Surgical options for MEN1-associated PHPT include:

Both approaches carry a risk of permanent hypoparathyroidism requiring lifelong calcium and calcitriol supplementation. Experienced endocrine surgeons with high-volume MEN1 caseloads achieve better outcomes. Medical management with cinacalcet (a calcimimetic) can reduce calcium levels but does not shrink glands and is not curative; it is generally reserved for patients unfit for surgery or those with mild asymptomatic disease who decline an operation.

Annual surveillance post-surgery measures serum calcium and PTH. Recurrence is detected early enough for repeat surgery in the majority of patients followed in specialty centers.

Back to Table of Contents

5. Pancreatic and GI Neuroendocrine Tumors (pNETs)

Pancreatic and duodenal neuroendocrine tumors (pNETs) develop in 30–75% of MEN1 patients over a lifetime, with prevalence rising sharply with age. They represent the leading cause of MEN1-related mortality, because — unlike parathyroid disease — a proportion of pNETs are malignant or have malignant potential. The pancreas and duodenum in MEN1 are remarkable for harboring dozens to hundreds of microscopic neuroendocrine tumors simultaneously, only some of which will enlarge to clinical significance.

Gastrinoma and Zollinger-Ellison Syndrome (ZES)

Gastrinoma is the most common functional pNET in MEN1, responsible for 50–60% of functioning pNETs. The vast majority of MEN1-associated gastrinomas arise not in the pancreas itself but in the wall of the duodenum — the gastrinoma triangle defined by the cystic duct, second and third portions of the duodenum, and the junction of the head and body of the pancreas. They are typically multiple, subcentimeter, and scattered throughout this region, which is why surgical cure is far harder to achieve than in sporadic single gastrinomas.

Excess gastrin from the tumor drives Zollinger-Ellison syndrome: relentless gastric acid hypersecretion causing refractory peptic ulcers (often multiple, often in atypical locations such as the jejunum), severe diarrhea and steatorrhea from acid inactivating pancreatic enzymes, and esophagitis. Before proton pump inhibitors (PPIs) became available, ZES was frequently fatal from bleeding ulcers. Today, high-dose PPIs (omeprazole or lansoprazole, often at doses double or triple standard) reliably control acid secretion and dramatically reduce ulcer-related morbidity. Long-term PPI use at these doses is generally safe.

Diagnosis of ZES involves demonstration of a fasting serum gastrin above 10 times the upper limit of normal (or above 1,000 pg/mL) combined with a gastric pH below 2. A secretin stimulation test — intravenous secretin produces a paradoxical rise in gastrin of more than 120 pg/mL within 10 minutes — confirms ZES when fasting gastrin is ambiguously elevated (between 200 and 1,000 pg/mL). Tumor localization uses endoscopic ultrasound (EUS), which detects subcentimeter duodenal tumors that CT misses, combined with somatostatin receptor scintigraphy (Octreoscan) or 68Ga-DOTATATE PET, which identifies both primary tumors and distant metastases.

The role of surgery in MEN1-ZES remains controversial. Because gastrinomas in MEN1 are virtually always multiple and not amenable to curative resection, most expert centers do not recommend routine surgery for ZES alone when tumors are below 2–2.5 cm and there is no evidence of lymph node or hepatic metastasis. Surgery is indicated for tumors larger than 2–2.5 cm in the pancreas, given their higher malignant potential. When surgical exploration is performed, distal pancreatectomy plus enucleation of pancreatic head tumors plus duodenotomy with excision of duodenal wall gastrinomas plus regional lymphadenectomy achieves biochemical cure in only 0–16% of MEN1-ZES patients at five years — far inferior to the 45–60% cure rates seen in sporadic single gastrinoma.

Insulinoma

Insulinoma occurs in 10–20% of MEN1 patients and causes hypoglycemia — the Whipple triad of symptoms (sweating, palpitations, confusion), a serum glucose below 55 mg/dL at the time of symptoms, and prompt resolution with glucose administration. Like other MEN1 pNETs, insulinomas in MEN1 are frequently multiple and scattered through the pancreas, contrasting with sporadic insulinomas, which are almost always solitary. Medical management with diazoxide (suppresses insulin release) or octreotide provides temporary relief, but surgery — typically subtotal or distal pancreatectomy with enucleation of additional nodules — is ultimately required for sustained control. Intraoperative ultrasound helps identify small insulinomas not detected preoperatively.

Non-Functioning pNETs

Non-functioning pNETs (NF-pNETs) are the most common pNETs found at autopsy in MEN1 patients — present in over 80% of autopsy series — but they are clinically silent because they do not secrete hormones in amounts sufficient to cause a clinical syndrome (though they may secrete pancreatic polypeptide, chromogranin A, or neuron-specific enolase detectable in blood). They grow slowly and silently over years to decades. The concern is malignant transformation: tumors below 1 cm carry very low malignant risk; those above 2 cm have substantially higher rates of lymph node and liver metastasis. Current guidelines recommend surgical resection for NF-pNETs larger than 2 cm, and some centers operate at 1.5 cm given imaging uncertainty about exact size. Annual pancreatic imaging by MRI or EUS is essential to track growth.

Back to Table of Contents

6. Pituitary Adenomas

Anterior pituitary adenomas develop in 30–40% of MEN1 patients, typically in the third or fourth decade of life but occasionally in childhood. MEN1-associated pituitary adenomas tend to be larger (macroadenomas above 1 cm) and more locally invasive than sporadic pituitary adenomas, with a higher rate of cavernous sinus invasion making complete surgical resection more difficult.

Prolactinoma

Prolactin-secreting adenomas (prolactinomas) account for approximately 70% of MEN1 pituitary tumors, mirroring their dominance in sporadic pituitary disease. Elevated prolactin causes amenorrhea and galactorrhea in premenopausal women, and erectile dysfunction, reduced libido, infertility, and gynecomastia in men. Both sexes may experience headache and visual field defects if the adenoma compresses the optic chiasm. Diagnosis is confirmed by a serum prolactin above 200 ng/mL (values 25–200 require exclusion of other causes including medications). First-line treatment is dopamine agonist therapy with cabergoline (preferred over bromocriptine for its weekly dosing and better tolerability). The majority of prolactinomas shrink significantly on cabergoline, with prolactin normalization in 80–90% of patients. Surgery is reserved for adenomas causing vision loss not controlled by medical therapy, or for patients intolerant of or resistant to dopamine agonists.

GH-Secreting Adenomas and Acromegaly

Growth hormone-secreting adenomas account for approximately 25% of MEN1 pituitary tumors. Chronic GH excess causes acromegaly: progressive enlargement of hands, feet, and facial features (coarsening, jaw prognathism, frontal bossing), excessive sweating, joint pain, obstructive sleep apnea, hypertension, glucose intolerance, and increased risk of colon polyps and potentially colorectal cancer. Diagnosis requires demonstration of non-suppressible GH on a 75g oral glucose tolerance test (GH nadir above 1 ng/mL) plus elevated IGF-1 for age and sex. Treatment options include trans-sphenoidal surgery (curative in approximately 50%), somatostatin analogues (octreotide LAR, lanreotide), the GH receptor antagonist pegvisomant, and stereotactic radiosurgery (Gamma Knife).

ACTH-Secreting Adenomas and Cushing's Disease

ACTH-secreting pituitary adenomas cause pituitary-dependent Cushing's disease in approximately 5% of MEN1 pituitary tumor cases. Clinical features include central obesity, purple striae, proximal muscle weakness, hypertension, glucose intolerance, easy bruising, and mood disturbance. Diagnosis requires demonstration of hypercortisolism (24-hour urinary free cortisol, late-night salivary cortisol, low-dose dexamethasone suppression test) followed by localization with pituitary MRI and, when MRI is non-localizing, bilateral inferior petrosal sinus sampling (BIPSS) to confirm the pituitary as the source. Trans-sphenoidal surgery is the primary treatment; remission rates depend on tumor size and surgeon experience.

Non-Functioning Pituitary Adenomas

Non-functioning pituitary adenomas that do not secrete identifiable hormones in clinically significant amounts represent a minority of MEN1 pituitary tumors. They are discovered either incidentally on surveillance MRI or because their mass effect causes headache and visual field deficits from chiasmal compression. Treatment is surgical when visual compromise is present or when the adenoma is growing rapidly on serial imaging.

Back to Table of Contents

7. Other Manifestations

Beyond the classical Three P's, MEN1 encompasses a spectrum of additional tumor types that contribute substantially to morbidity and, in the case of foregut carcinoids, to mortality.

Adrenocortical Tumors

Adrenocortical tumors develop in 30–40% of MEN1 patients. They are typically bilateral, non-functioning (do not secrete cortisol, aldosterone, or androgens in excess), and detected incidentally on surveillance abdominal imaging. The vast majority are benign adrenocortical adenomas. Adrenocortical carcinoma is rare in MEN1 but has been reported. The primary concern in managing MEN1-associated adrenal tumors is the same as for sporadic adrenal incidentalomas: annual biochemical screening for subclinical hormonal excess (overnight dexamethasone suppression, plasma aldosterone-to-renin ratio, plasma or 24-hour urine metanephrines) and consideration of adrenalectomy for tumors showing growth above 4 cm or imaging features concerning for malignancy.

Thymic Carcinoids

Thymic neuroendocrine tumors (thymic carcinoids) occur in approximately 2–8% of MEN1 patients and represent one of the most dangerous complications. They disproportionately affect male MEN1 carriers who smoke, in whom the cumulative risk approaches 20%. Thymic carcinoids are often clinically silent until locally advanced, do not produce ectopic ACTH (the majority are non-functional), and carry a poor prognosis — five-year survival below 30% in some series because of late detection and propensity for local invasion and distant metastasis. All MEN1 carriers should undergo chest CT every 1–2 years regardless of symptoms. The discovery of a thymic mass in a MEN1 patient warrants prompt surgical exploration. Prophylactic thymectomy at the time of parathyroid surgery has been advocated by some groups, particularly for male smokers, though evidence for survival benefit is limited.

Bronchial Carcinoids

Bronchopulmonary neuroendocrine tumors (bronchial carcinoids) occur in approximately 5% of MEN1 patients, with a stronger predisposition in women compared with thymic carcinoids. Most are well-differentiated typical carcinoids with an indolent course and good prognosis after surgical resection. They are detected on chest CT surveillance. Carcinoid syndrome (flushing, diarrhea from serotonin) is rare because hepatic passage efficiently metabolizes serotonin before it reaches the systemic circulation.

Gastric ECL-Cell Carcinoids (Type II)

Type II gastric neuroendocrine tumors (ECL-cell gastric carcinoids) are driven by the hypergastrinemia of ZES: chronic gastrin stimulation induces hyperplasia of enterochromaffin-like (ECL) cells in the gastric body, eventually forming multiple small carcinoid tumors. Unlike the more common Type I gastric carcinoids (driven by autoimmune achlorhydria), Type II tumors occur in the specific setting of ZES-MEN1. They are generally multiple, less than 1 cm, and behave in an indolent fashion. Treatment of the underlying ZES with PPI therapy and, where feasible, tumor resection often stabilizes the gastric lesions. Endoscopic surveillance of the gastric mucosa is performed during upper endoscopy for ZES monitoring.

Cutaneous Manifestations

Skin findings are present in the majority of MEN1 carriers and are sometimes the first clue to the diagnosis. They include:

Meningiomas and Other CNS Tumors

Meningiomas are documented in a small subset of MEN1 patients (approximately 5–8%) and may arise earlier than sporadic meningiomas. They are typically benign and are managed by standard neurosurgical criteria (size, symptoms, growth rate). Other rare CNS associations include ependymomas.

Back to Table of Contents

8. Diagnosis and Surveillance Protocol

The diagnosis of MEN1 is established by one of three criteria: (1) the presence of two or more primary MEN1-associated endocrine tumors in an individual; (2) one MEN1-associated tumor in a first-degree relative of a confirmed MEN1 patient; or (3) a pathogenic germline MEN1 mutation identified by genetic testing, regardless of clinical findings at the time.

Genetic testing is recommended for all first-degree relatives of a confirmed MEN1 patient. Testing is offered from age 5 in some protocols (given rare childhood-onset parathyroid disease) and from age 10 in most guidelines. Sequencing of the entire MEN1 coding region plus exon-flanking intronic sequences, combined with deletion/duplication analysis (MLPA), detects a pathogenic variant in approximately 70–90% of clinically confirmed MEN1 families. A negative result in a family with a known mutation reliably excludes MEN1 carrier status in the tested individual, who can then be discharged from surveillance. A negative result in a family without an identified mutation does not fully exclude MEN1 and may require continued clinical surveillance.

Once a patient is confirmed (clinically or genetically) to have MEN1, the following annual surveillance protocol is recommended by major clinical guidelines (Thakker et al. 2012):

For newly diagnosed patients or those presenting with symptomatic disease, a complete baseline assessment of all organ systems is performed simultaneously, because identifying co-existing tumors at other sites changes the surgical and medical management plan — for example, controlling hypercalcemia before pNET surgery, or treating ZES with PPI before correcting PHPT.

Back to Table of Contents

9. Treatment Principles

Treatment in MEN1 differs from sporadic endocrine tumor management in several fundamental ways:

Prognosis in MEN1 has improved substantially over the past three decades with earlier diagnosis through genetic testing, better biochemical surveillance, advanced imaging, and expanded medical and surgical options. The main drivers of reduced life expectancy compared with the general population are malignant pNETs (particularly gastrinoma with hepatic metastases) and thymic carcinoids. Patients with well-controlled disease and no malignant tumors can live normal lifespans.

Back to Table of Contents

10. Research Papers

The following peer-reviewed publications provide the foundational evidence for MEN1 diagnosis, genetics, and management.

  1. Thakker RV, et al. "Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1)." J Clin Endocrinol Metab. 2012;97(9):2990-3011. PMID: 22723327
  2. Lemos MC, Thakker RV. "Multiple endocrine neoplasia type 1 (MEN1): analysis of 1336 mutations reported in the first decade following identification of the gene." Hum Mutat. 2008;29(1):22-32. PMID: 17879353
  3. Walls GV. "Multiple endocrine neoplasia (MEN) syndromes." Semin Pediatr Surg. 2014;23(2):96-101. PMID: 24931352
  4. Jensen RT, et al. "Gastrinoma (Zollinger-Ellison Syndrome)." Adv Exp Med Biol. 2010;654:261-316. PMID: 20217503
  5. Norton JA, et al. "Surgical treatment and prognosis of gastrinoma." Best Pract Res Clin Gastroenterol. 2012;26(6):759-769. PMID: 23582916
  6. Vierimaa O, et al. "Pituitary adenoma predisposition caused by germline mutations in the AIP gene." Science. 2006;312(5777):1228-1230. PMID: 16728643
  7. Burgess JR, et al. "Surgical therapy for gastrinomas in multiple endocrine neoplasia type 1." Arch Surg. 1996;131(2):130-135. PMID: 8596390
  8. Dreijerink KM, et al. "Menin links estrogen receptor activation to histone H3K4 trimethylation." Cancer Res. 2006;66(9):4929-4935. PMID: 16651449
  9. Thakker RV. "Multiple endocrine neoplasia type 1 (MEN1) and type 4 (MEN4)." Mol Cell Endocrinol. 2014;386(1-2):2-15. PMID: 23933118
  10. Newey PJ, et al. "Parafibromin—functional insights." J Intern Med. 2009;266(1):84-98. PMID: 19522827
  11. Falchetti A, et al. "Multiple endocrine neoplasia type 1 (MEN1): not just a tumor suppressor gene." Expert Rev Endocrinol Metab. 2009;4(5):493-506. PMID: 30780782
  12. Chandrasekharappa SC, et al. "Positional cloning of the gene for multiple endocrine neoplasia-type 1." Science. 1997;276(5311):404-407. PMID: 9103196

Back to Table of Contents

Connections

Back to Table of Contents